BioNTech Price To Operating Cash Flows Ratio from 2010 to 2024

BNTX Stock  USD 114.22  6.16  5.12%   
BioNTech Price To Operating Cash Flows Ratio yearly trend continues to be fairly stable with very little volatility. Price To Operating Cash Flows Ratio is likely to outpace its year average in 2024. During the period from 2010 to 2024, BioNTech Price To Operating Cash Flows Ratio regression line of annual values had significance of  0.72 and arithmetic mean of (105.48). View All Fundamentals
 
Price To Operating Cash Flows Ratio  
First Reported
2010-12-31
Previous Quarter
4.31775933
Current Value
4.53
Quarterly Volatility
295.17139339
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as Tax Provision of 243 M, Net Interest Income of 367.2 M or Interest Income of 375.5 M, as well as many indicators such as Price To Sales Ratio of 5.77, Dividend Yield of 0.0111 or PTB Ratio of 1.2. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
  
Check out the analysis of BioNTech Correlation against competitors.

Latest BioNTech's Price To Operating Cash Flows Ratio Growth Pattern

Below is the plot of the Price To Operating Cash Flows Ratio of BioNTech SE over the last few years. It is BioNTech's Price To Operating Cash Flows Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.
Price To Operating Cash Flows Ratio10 Years Trend
Very volatile
   Price To Operating Cash Flows Ratio   
       Timeline  

BioNTech Price To Operating Cash Flows Ratio Regression Statistics

Arithmetic Mean(105.48)
Coefficient Of Variation(279.85)
Mean Deviation141.34
Median(51.20)
Standard Deviation295.17
Sample Variance87,126
Range1.2K
R-Value(0.10)
Mean Square Error92,881
R-Squared0.01
Significance0.72
Slope(6.63)
Total Sum of Squares1.2M

BioNTech Price To Operating Cash Flows Ratio History

2024 4.53
2023 4.32
2022 2.51
2021 62.17
2020 -1165.5
2019 -32.18
2018 -48.42

About BioNTech Financial Statements

BioNTech investors use historical fundamental indicators, such as BioNTech's Price To Operating Cash Flows Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioNTech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price To Operating Cash Flows Ratio 4.32  4.53 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.